OBJECTIVE: This study examined the impact of insurance parity on the use, cost, and quality of substance abuse treatment. METHODS: The authors compared substance abuse treatment spending and utilization from 1999 to 2002 for continuously enrolled beneficiaries covered by Federal Employees Health Benefit (FEHB) plans, which require parity coverage of mental health and substance use disorders, with spending and utilization among beneficiaries in a matched set of health plans without parity coverage. Logistic regression models estimated the probability of any substance abuse service use. Conditional on use, linear models estimated total and out-of-pocket spending. Logistic regression models for three quality indicators for substance abuse treatment were also estimated: identification of adult enrollees with a new substance abuse diagnosis, treatment initiation, and treatment engagement. Difference-in-difference estimates were computed as (postparity - preparity) differences in outcomes in plans without parity subtracted from those in FEHB plans. RESULTS: There were no significant differences between FEHB and non-FEHB plans in rates of change in average utilization of substance abuse services. Conditional on service utilization, the rate of substance abuse treatment out-of-pocket spending declined significantly in the FEHB plans compared with the non-FEHB plans (mean difference=-$101.09, 95% confidence interval [CI]=-$198.06 to -$4.12), whereas changes in total plan spending per user did not differ significantly. With parity, more patients had new diagnoses of a substance use disorder (difference-in-difference risk=.10%, CI=.02% to .19%). No statistically significant differences were found for rates of initiation and engagement in substance abuse treatment. CONCLUSIONS: Findings suggest that for continuously enrolled populations, providing parity of substance abuse treatment coverage improved insurance protection but had little impact on utilization, costs for plans, or quality of care.
OBJECTIVE: This study examined the impact of insurance parity on the use, cost, and quality of substance abuse treatment. METHODS: The authors compared substance abuse treatment spending and utilization from 1999 to 2002 for continuously enrolled beneficiaries covered by Federal Employees Health Benefit (FEHB) plans, which require parity coverage of mental health and substance use disorders, with spending and utilization among beneficiaries in a matched set of health plans without parity coverage. Logistic regression models estimated the probability of any substance abuse service use. Conditional on use, linear models estimated total and out-of-pocket spending. Logistic regression models for three quality indicators for substance abuse treatment were also estimated: identification of adult enrollees with a new substance abuse diagnosis, treatment initiation, and treatment engagement. Difference-in-difference estimates were computed as (postparity - preparity) differences in outcomes in plans without parity subtracted from those in FEHB plans. RESULTS: There were no significant differences between FEHB and non-FEHB plans in rates of change in average utilization of substance abuse services. Conditional on service utilization, the rate of substance abuse treatment out-of-pocket spending declined significantly in the FEHB plans compared with the non-FEHB plans (mean difference=-$101.09, 95% confidence interval [CI]=-$198.06 to -$4.12), whereas changes in total plan spending per user did not differ significantly. With parity, more patients had new diagnoses of a substance use disorder (difference-in-difference risk=.10%, CI=.02% to .19%). No statistically significant differences were found for rates of initiation and engagement in substance abuse treatment. CONCLUSIONS: Findings suggest that for continuously enrolled populations, providing parity of substance abuse treatment coverage improved insurance protection but had little impact on utilization, costs for plans, or quality of care.
Authors: Deborah W Garnick; Margaret T Lee; Mady Chalk; David Gastfriend; Constance M Horgan; Frank McCorry; A Thomas McLellan; Elizabeth Levy Merrick Journal: J Subst Abuse Treat Date: 2002-12
Authors: Howard H Goldman; Richard G Frank; M Audrey Burnam; Haiden A Huskamp; M Susan Ridgely; Sharon-Lise T Normand; Alexander S Young; Colleen L Barry; Vanessa Azzone; Alisa B Busch; Susan T Azrin; Garrett Moran; Carolyn Lichtenstein; Margaret Blasinsky Journal: N Engl J Med Date: 2006-03-30 Impact factor: 91.245
Authors: Deborah W Garnick; Constance M Horgan; Margaret T Lee; Lee Panas; Grant A Ritter; Steve Davis; Tracy Leeper; Rebecca Moore; Mark Reynolds Journal: J Subst Abuse Treat Date: 2007-05-23
Authors: Alisa B Busch; Haiden A Huskamp; Sharon-Lise T Normand; Alexander S Young; Howard Goldman; Richard G Frank Journal: Med Care Date: 2006-06 Impact factor: 2.983
Authors: Howard H Goldman; Colleen L Barry; Sharon-Lise T Normand; Vanessa Azzone; Alisa B Busch; Haiden A Huskamp Journal: Psychiatr Serv Date: 2012-02-01 Impact factor: 3.084
Authors: Theresa Ann Sipe; Ramona K C Finnie; John A Knopf; Shuli Qu; Jeffrey A Reynolds; Anilkrishna B Thota; Robert A Hahn; Ron Z Goetzel; Kevin D Hennessy; Lela R McKnight-Eily; Daniel P Chapman; Clinton W Anderson; Susan Azrin; Ana F Abraido-Lanza; Alan J Gelenberg; Mary E Vernon-Smiley; Donald E Nease Journal: Am J Prev Med Date: 2015-06 Impact factor: 5.043
Authors: Colleen L Barry; Alyna T Chien; Sharon-Lise T Normand; Alisa B Busch; Vanessa Azzone; Howard H Goldman; Haiden A Huskamp Journal: Pediatrics Date: 2013-02-18 Impact factor: 7.124
Authors: Hefei Wen; Janet R Cummings; Jason M Hockenberry; Laura M Gaydos; Benjamin G Druss Journal: JAMA Psychiatry Date: 2013-12 Impact factor: 21.596
Authors: Verughese Jacob; Shuli Qu; Sajal Chattopadhyay; Theresa Ann Sipe; John A Knopf; Ron Z Goetzel; Ramona Finnie; Anilkrishna B Thota Journal: J Ment Health Policy Econ Date: 2015-03
Authors: Alisa B Busch; Frank Yoon; Colleen L Barry; Vanessa Azzone; Sharon-Lise T Normand; Howard H Goldman; Haiden A Huskamp Journal: Am J Psychiatry Date: 2013-02 Impact factor: 18.112
Authors: Mari-Lynn Drainoni; Caitlin Farrell; Amy Sorensen-Alawad; Joseph N Palmisano; Christine Chaisson; Alexander Y Walley Journal: AIDS Patient Care STDS Date: 2014-01-15 Impact factor: 5.078
Authors: Susan H Busch; Andrew J Epstein; Michael O Harhay; David A Fiellin; Hyong Un; Deane Leader; Colleen L Barry Journal: Am J Manag Care Date: 2014 Impact factor: 2.229